title: [Docetaxel-induced acute pulmonary capillary-leak syndrome mimicking cardiogenic oedema].
authors.forename: R
authors.initials: R
authors.lastname: Amathieu
authors.forename: L
authors.initials: L
authors.lastname: Tual
authors.forename: C
authors.initials: C
authors.lastname: Fessenmeyer
authors.forename: G
authors.initials: G
authors.lastname: Dhonneur
mesh_terms: D000208:Acute Disease; D000925:Anticoagulants / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D019559:Capillary Leak Syndrome / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D003937:Diagnosis, Differential; D000077143:Docetaxel; D004305:Dose-Response Relationship, Drug; D004489:Edema, Cardiac / Q000175:diagnosis*; D005260:Female; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008775:Methylprednisolone / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D011654:Pulmonary Edema / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D011655:Pulmonary Embolism / Q000175:diagnosis / Q000517:prevention & control; D012008:Recurrence; D012121:Respiration, Artificial; D013125:Spinal Neoplasms / Q000188:drug therapy / Q000556:secondary; D043823:Taxoids / Q000009:adverse effects* / Q000627:therapeutic use; D000078222:Tinzaparin
chemical_list: D000925:Anticoagulants; D000972:Antineoplastic Agents, Phytogenic; D006495:Heparin, Low-Molecular-Weight; D043823:Taxoids; D000077143:Docetaxel; D000078222:Tinzaparin; D008775:Methylprednisolone